Elias Jabbour1, Dinara Makenbaeva2, Melissa Lingohr-Smith3, Jay Lin3. 1. The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: ejabbour@mdanderson.org. 2. Bristol-Myers Squibb, Princeton, NJ. 3. Novosys Health, Green Brook, NJ.
Abstract
BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines state that based on toxicity profiles, 1 second-generation tyrosine kinase inhibitor (TKI) indicated for first-line therapy (ie, dasatinib, nilotinib) may be preferred over the other for treatment of chronic myelogenous leukemia (CML) patients with certain comorbidities. This study assessed the prevalence of comorbid conditions relevant to TKI treatment choice among CML patients in the US real-world setting. PATIENTS AND METHODS: Patients who had CML and initiated TKI treatment were identified from the MarketScan Commercial and Medicare databases (January 1, 2006, to June 30, 2013). Demographics and prevalence of comorbid conditions relevant to TKI treatment choice per NCCN guidelines (heart disease, arrhythmia, diabetes, pancreatitis, pleural effusion, lung disease) were assessed among the overall study population and among subgroups. RESULTS: The median age of the CML study population newly initiated on TKI treatment (ie, imatinib, dasatinib, or nilotinib; n = 2296) was 56 years. Approximately 41% of the CML study population had at least 1 comorbid condition that may influence the choice of TKI treatment as recommended by NCCN guidelines. The most prevalent comorbid condition was heart disease (23%), followed by diabetes (18%) and lung disease (13%). The prevalence of comorbid conditions relevant to TKI treatment choice varied among patients of different age groups, gender, and US regions. CONCLUSION: The results of this analysis provide real-world evidence that the prevalence of relevant comorbid conditions is substantial among CML patients in the US managed care setting and therefore needs to be considered throughout various health care decision-making processes related to CML.
BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines state that based on toxicity profiles, 1 second-generation tyrosine kinase inhibitor (TKI) indicated for first-line therapy (ie, dasatinib, nilotinib) may be preferred over the other for treatment of chronic myelogenous leukemia (CML) patients with certain comorbidities. This study assessed the prevalence of comorbid conditions relevant to TKI treatment choice among CMLpatients in the US real-world setting. PATIENTS AND METHODS: Patients who had CML and initiated TKI treatment were identified from the MarketScan Commercial and Medicare databases (January 1, 2006, to June 30, 2013). Demographics and prevalence of comorbid conditions relevant to TKI treatment choice per NCCN guidelines (heart disease, arrhythmia, diabetes, pancreatitis, pleural effusion, lung disease) were assessed among the overall study population and among subgroups. RESULTS: The median age of the CML study population newly initiated on TKI treatment (ie, imatinib, dasatinib, or nilotinib; n = 2296) was 56 years. Approximately 41% of the CML study population had at least 1 comorbid condition that may influence the choice of TKI treatment as recommended by NCCN guidelines. The most prevalent comorbid condition was heart disease (23%), followed by diabetes (18%) and lung disease (13%). The prevalence of comorbid conditions relevant to TKI treatment choice varied among patients of different age groups, gender, and US regions. CONCLUSION: The results of this analysis provide real-world evidence that the prevalence of relevant comorbid conditions is substantial among CMLpatients in the US managed care setting and therefore needs to be considered throughout various health care decision-making processes related to CML.
Authors: Guray Saydam; Ridvan Ali; Ahmet Muzaffer Demir; Ahmet Emre Eskazan; Birol Guvenc; Ibrahim Celalettin Haznedaroglu; Mehmet Ali Ozcan; Ozan Salim; Mehmet Sonmez; Ayse Tulin Tuglular; Mehmet Turgut; Ali Unal; Birkan Aver; Sirac Bozkurt; Begum Ozdengulsun; Osman Ilhan Journal: Int J Hematol Oncol Date: 2022-05-24
Authors: Sergiy Kostenko; Chan C Heu; Jordan R Yaron; Garima Singh; Cristiane de Oliveira; William J Muller; Vijay P Singh Journal: Sci Rep Date: 2018-08-09 Impact factor: 4.379
Authors: Rory M Shallis; Rong Wang; Jan P Bewersdorf; Amer M Zeidan; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Xiaomei Ma Journal: Ther Adv Hematol Date: 2021-11-30
Authors: Carolien C H M Maas; David van Klaveren; Geneviève I C G Ector; Eduardus F M Posthuma; Otto Visser; Peter E Westerweel; Jeroen J W M Janssen; Nicole M A Blijlevens; Avinash G Dinmohamed Journal: Br J Haematol Date: 2021-12-05 Impact factor: 8.615